My Top High-Conviction Home Run Stock

Although home run stocks, or equities capable of producing life-altering returns in a short period of time, are far from commonplace, the biopharmaceutical industry has been fertile ground for explosive growth vehicles for a number of years now. The core reason is the industry's ongoing innovation bonanza. While developing pharmaceuticals is fraught with risk at nearly every step, several clinical-stage biotechs have, in fact, overcome these long odds over the past 10 years to bring important new medicines to market. And the market has often richly rewarded the select few biopharmas that have successfully transitioned from a clinical-stage company to a commercial operation. Aurinia Pharmaceuticals, Catalyst Pharmaceuticals, and Novavax are just a few of the more recent examples: